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Abstract Nicotinic acid (NiAc) is a potent inhibitor of
adipose tissue lipolysis. Acute administration results in a
rapid reduction of plasma free fatty acid (FFA) concen-
trations. Sustained NiAc exposure is associated with tol-
erance development (drug resistance) and complete
adaptation (FFA returning to pretreatment levels). We
conducted a meta-analysis on a rich pre-clinical data set of
the NiAc–FFA interaction to establish the acute and
chronic exposure-response relations from a macro per-
spective. The data were analyzed using a nonlinear mixed-
effects framework. We also developed a new turnover
model that describes the adaptation seen in plasma FFA
concentrations in lean Sprague–Dawley and obese Zucker
rats following acute and chronic NiAc exposure. The
adaptive mechanisms within the system were described
using integral control systems and dynamic efficacies in the
traditional Imax model. Insulin was incorporated in parallel
with NiAc as the main endogenous co-variate of FFA
dynamics. The model captured profound insulin resistance
and complete drug resistance in obese rats. The efficacy of
NiAc as an inhibitor of FFA release went from 1 to
approximately 0 during sustained exposure in obese rats.
The potency of NiAc as an inhibitor of insulin and of FFA
release was estimated to be 0.338 and 0.436 lM, respec-
tively, in obese rats. A range of dosing regimens was
analyzed and predictions made for optimizing NiAc
delivery to minimize FFA exposure. Given the exposure
levels of the experiments, the importance of washout
periods in-between NiAc infusions was illustrated. The
washout periods should be  2 h longer than the infusions
in order to optimize 24 h lowering of FFA in rats. How-
ever, the predicted concentration-response relationships
suggests that higher AUC reductions might be attained at
lower NiAc exposures.
Keywords Meta-analysis  Turnover models  Nonlinear
mixed-effects (NLME)  Tolerance  Disease modeling 
Dosing regimen
Introduction
Nicotinic acid (NiAc; or niacin) has long been used to treat
dyslipidemia [1, 2]. When given in large doses (1–3 g/day),
NiAc improves the plasma lipid profile by reducing total
cholesterol, triglycerides, low-density lipoprotein choles-
terol, and very-low-density lipoprotein cholesterol, and
increasing levels of high-density lipoprotein cholesterol
[3]. Moreover, by binding to the G-protein coupled
receptor GPR109A, NiAc potently inhibits lipolysis in
adipose tissue, leading to decreased plasma free fatty acid
(FFA) concentrations [4, 5]. The mechanisms of NiAc-
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induced antilipolysis have been thoroughly analyzed in
previous studies [6–9]. Chronically elevated plasma FFA
concentrations are associated with several metabolic dis-
eases, including insulin resistance [10–12]; NiAc-induced
FFA lowering is a potential approach to ameliorating these
conditions. However, the clinically applied dosing regi-
mens have not been designed to lower FFA; rather, the goal
has been to ameliorate dyslipidemia [13].
Although acute administration of NiAc results in rapid
reduction in FFA concentrations [2, 14], long-term infusions
are associated with tolerance development (drug resistance)
and plasma FFA concentrations returning to pre-treatment
levels (complete adaptation) [15]. Furthermore, abrupt ces-
sation of the NiAc infusions produces an FFA rebound that
overshoots the pre-infusion levels [9, 15]. Numerous studies
have sought to quantitatively determine the acute concentra-
tion-response relationship between NiAc and FFA
[14, 16–23]. The acute NiAc-induced FFA response has been
successfully characterized using pharmacokinetic/pharma-
codynamic (PK/PD) models, but these models fail to describe
the complete return of FFA to pretreatment levels associated
with chronic NiAc treatment. Thus, an improved model is
required in order to predict optimal treatment regimens, aimed
to achieve durable NiAc-induced FFA lowering.
In this study, we sought to further develop the concepts
used in previous analyses to develop a more general NiAc-
FFA interaction model—applicable to a large set of dosing
regimens and NiAc exposure durations. The model was also
aimed at quantitatively determining the impact of disease on
the FFA-insulin system and to provide predictions for opti-
mal drug delivery. We conducted a meta-analysis on a rich
pre-clinical data set of the interaction between NiAc and
FFA, as well as insulin, in a nonlinear mixed-effects (NLME)
modeling framework. Using various routes and modes of
NiAc provocations, we collected concentration-time course
data of NiAc (drug kinetics), insulin and FFA (drug-induced
dynamics). Experiments were done both in lean Sprague-
Dawley and obese Zucker rats—allowing disease impact to
be evaluated. Furthermore, by including insulin as a co-
variate of the FFA response, we could quantitatively analyze
the endogenous antilipolytic effects of insulin [24] under
NiAc provocations. Moreover, optimal dosing regimens,
consisting of constant rate infusion periods followed by
washout periods, were investigated.
Methods
Animals
Male Sprague Dawley (lean) and Zucker rats (fa/fa, obese)
were purchased from (conscious groups) Harlan Labora-
tories B.V. (The Netherlands) or (anesthetized groups)
Charles River Laboratories (USA). Experimental proce-
dures were approved by the local Ethics Committee for
Animal Experimentation (Gothenburg region, Sweden).
Rats were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care accredited
facility with environmental control: 20–22 C, relative
humidity 40–60%, and 12 h light-dark cycle. During
acclimatization ( 5 days), animals were housed in groups
of 5 with free access to both water and standard rodent
chow (R70, Laktamin AB, Stockholm, Sweden).
Surgical preparations
To prevent potential infections in conjunction with surgery,
oral antibiotics were given 1 day before pump/catheter
surgery and then once daily for 3 days (sulfamethoxazole
and trimethoprim 40 ? 8 mg mL1; Bactrim , 0.2mL /
animal, Roche Ltd, Basel, Switzerland). Surgery was per-
formed under isoflurane (Forene, Abbott Scandinavia AB,
Solna, Sweden) anesthesia, with body temperature main-
tained at 37 C. For NiAc/saline administration, a pro-
grammable mini pump (iPrecio SMP200 Micro Infusion
Pump, Primetech Corporation, Tokyo, Japan) was
implanted subcutaneously, via a dorsal skin incision. To
allow blood sampling during the terminal experiment
(conscious animals only), a polyurethane catheter (Instech
Laboratories Inc, Plymouth Meeting, PA USA) was placed
in the right jugular vein via an incision in the neck. In order
to maintain its patency up to the acute experiment, the
jugular catheter was filled with sterile 45.5% (wt/wt) PVP
(polyvinylpyrrolidone, K30, MW  40,000 Fluka, Sigma-
Aldrich, Sweden) dissolved in a sodium-citrate solution
(20.6 mmol), sealed and exteriorized at the nape of the
neck. Each animal received a post-operative, subcutaneous
analgesic injection (buprenorphine, Temgesic, 1.85 lg
kg1, RB Pharmaceuticals Ltd, Berkshire, GB). Animals
were then housed individually and allowed three days of
recovery before the start of the pre-programmed pump
infusion. Throughout the study, body weight and general
health status were monitored and recorded daily.
Nicotinic acid exposure selection and formulation
A key aspect of the study design was to achieve plateau
plasma nicotinic acid (NiAc) concentrations corresponding
to therapeutically relevant levels in the rat ( 1 lM), based
on the relationship between plasma NiAc levels and FFA
lowering [16]. For intravenous infusions (i.v.), NiAc (pyr-
idine-3-carboxylic acid, Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in sterile saline. For subcutaneous (s.c.)
infusions, NiAc was dissolved in sterile water and adjusted to
physiological pH using sodium hydroxide. Vehicle, for
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control animals, consisted of sodium chloride solutions at
equimolar concentrations. Freshly prepared formulations
were loaded into the infusion pump (see below) via a 0.2 lm
sterile filter (Acrodisc, Pall Corporation, Ann Arbor, MI,
USA) just before pump implantation.
Experimental protocols
Conscious animals (NiAc naı¨ve, Cont. NiAc and Inter.
NiAc groups)
Both lean and obese animals were divided into 3 dose groups
and NiAc was given either acutely (NiAc naı¨ve) or following
5 days of either continuous (Cont. NiAc) or intermittent
(Inter. NiAc) administration. Each dose group was matched
with corresponding saline infused controls. NiAc infusions
were given subcutaneously at 170 nmol min1kg1. The
intermittent infusion protocol was programmed as a 12 h on-
off cycle (infusion on at 13:00). Following overnight fast, in
the morning of the acute experimental day, the jugular
catheter was connected to a swivel system to enable blood
sampling in unrestrained animals. Jugular catheter patency
was maintained by continuous infusion (5 lmol min1) of
sodium-citrate solution (20.6 mM). After a 3–4 h adaptation
period, at  12:00, the basal phase of the acute experiment
commenced with 2–3 blood samples drawn between -60
and -5 min, relative to start of NiAc/saline infusion (note
that, in the Cont. NiAc groups, infusion pumps were on
throughout this sampling period). Blood samples (16–17/
animal) were drawn under an 8 h experimental period.
Samples, 30–150 ll (with total loss less than 5% of blood
volume), were collected in potassium-EDTA tubes, cen-
trifuged and plasma stored at -80 C pending analysis for
NiAc, FFA and insulin.
Anesthetized animals (NiAc Off and NiAc Stp-Dwn 12 h
infusion groups)
Before the infusions began, lean and obese rats were fasted
for 8 h. On the day of the acute study, at 01:00 (corresponding
to time = 0 h), the implanted pre-programmed pump began
infusing NiAc at a constant rate of 170 nmol min1 kg1 for
12 h. At 8.5 h animals were anesthetized (Na-thiobutabar-
bitol, Inactin, 180 mg kg1, i.p., RBI, Natick, MA, USA),
underwent a tracheotomy with PE 240 tubing, and breathed
spontaneously. One catheter (PE 50 tubing) was placed in the
left carotid artery for blood sampling and for recording
arterial blood pressure and heart rate. One catheter (PE 10
tubing) was placed in the right external jugular vein to infuse
top-up doses of anesthetic. The arterial catheter patency was
maintained by continuous infusion of sodium-citrate
(20.6 mM in saline, 5 ll min1) from shortly after carotid
catheterization until the experiment ended. Body
temperature was monitored using a rectal thermocouple and
maintained at 37.5 C by means of servo controlled external
heating. After surgery, animals were allowed a stabilization
period of at least 1.5 h and blood sampling began at 11.0 h.
At 12.0 h, NiAc infusion was either programmed to switch
off (NiAc Off) or to decrease in a step-wise manner, with
final switch-off at 15.5 h (NiAc Stp-Dwn). The step-down
NiAc infusion rates were 88.9, 58.3, 43.7, 34.0, 24.3, 17.0,
and 9.7 nmol min1 kg1. All NiAc protocols were matched
with saline-infused controls. Blood samples (18/animal)
were drawn during a 6 h experimental period. Samples, 30–
150 ll (with total loss less than 5% of blood volume), were
collected in potassium-EDTA tubes, centrifuged, and
plasma was stored at -80 C pending analysis for NiAc,
FFA and insulin.
Anesthetized animals (NiAc Off and NiAc Stp-Dwn 1 h
infusion groups)
After an overnight fast, lean and obese rats were anes-
thetized and surgically prepared, as described above. They
were allowed a stabilization period after surgery of at least
1.5 h. Two basal blood samples were obtained, after which
an i.v. NiAc infusion was given at a constant rate
(170 nmol min 1kg1) for 1.0 h (the start of infusion was
taken as time = 0 h). The NiAc infusion was then either
switched off (NiAc-Off 1 h) or decreased in a step-wise
manner, with final switch-off at 4.5 h (NiAc Stp-Dwn 1 h).
The step-down NiAc infusion rates were: 31.1, 20.4, 15.3,
11.9, 8.50, 5.95 and 3.40 nmol min1kg1. All NiAc pro-
tocols were matched with saline infused controls. Blood
samples (13–18/animal) were drawn during a 6 h experi-
mental period. Samples, 30–150 ll (with total loss less
than 5% of blood volume), were collected in potassium-
EDTA tubes, centrifuged, and plasma was stored at
-80 C pending analysis for NiAc, FFA, and insulin. All
of the experimental groups are summarized in Table 1.
Analytical methods
Plasma FFA was analyzed using an enzymatic colorimetric
method (Wako Chemicals GmbH, Neuss, Germany).
Plasma insulin from obese rats was analyzed with a
radioimmunoassay kit (rat insulin RIA kit, Millipore Cor-
poration, St. Charles, Missouri, USA). Plasma insulin
concentrations from lean rats were determined using a
colorimetric ELISA kit (Ultra Sensitive Rat Insulin ELISA
Kit, Crystal Chem INC, Downers Grove, IL, USA). The
ELISA was used for lean rats to minimize blood sample
volume (only 5 ll plasma required vs.  50 ll plasma for
RIA). The RIA was used for the obese rats because their
high lipid levels in plasma interfere with the ELISA but not
the RIA measurement. Due to the hyperinsulinemia in the
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obese rats only 5 ll of plasma was required. For lean-rat
plasma (with low lipid levels) the absolute insulin mea-
surements are equivalent for the RIA and ELISA assays,
according to an in-house comparison. Plasma NiAc con-
centrations were analyzed using LC-MS/MS with a
hydrophilic interaction liquid chromatography (HILIC)
approach, separated on a 502.1 mm Biobasic AX col-
umn, with 5 lm particles (Thermo Hypersil-Keystone,
Runcorn, Cheshire, UK) as previously described [16].
Model development
The exposure (PK) and biomarker (PD) models were
developed sequentially because of the interaction between
the model components; the kinetics of NiAc are assumed to
be unaffected by insulin and FFA, whereas NiAc inhibits
the release of both insulin and FFA. Furthermore, due to its
antilipolytic effect, insulin affects FFA release. The inter-
actions between the three models (NiAc, insulin, and FFA)
are illustrated in Fig. 1b, and model interactions of previ-
ously published NiAc-FFA models [14, 19, 20, 23] are
illustrated in Fig. 1a for comparison. When a sub-model
had been estimated, the random effects were fixed to the
Empirical Bayes Estimates (EBE) and used as covariates in
the subsequent sub-model.
Disease modeling and inter-study variability
The PK and PD were significantly different between lean
(normal) and obese (diseased) rats and, consequently, these
groups were modeled separately. Furthermore, the animal
experiments were done under different conditions (separate
time periods, anesthetized/conscious animals) which may
have provoked different dynamic behaviors. To account for
this, inter-study variability was included in the models in
the form of fixed-study effects [25].
Notation conventions
To improve readability and enable the reader to differen-
tiate between separate sub-model parameters, PD (insulin
and FFA) model parameters are labeled with a subscript,
indicating to which model they belong. For example, the
turnover rate of FFA will be referred to as kinF and the
turnover rate of insulin is kinI (i.e., F for FFA and I for
insulin). Parameters that link NiAc, insulin, and FFA are
Fig. 1 Schematic illustration of how the dependency between NiAc
and FFA has been modeled in previous studies (a) and how the
dependencies between NiAc, insulin, and FFA were modeled in this
study (b). Solid lines represent fluxes while dashed lines represent
control. NiAc inhibits the turnover of insulin (1). Insulin, in turn, has
feedback mechanisms that inhibits its turnover (2) and stimulates its
fractional turnover (3). Both NiAc (4) and insulin (5) inhibit the
turnover of FFA. In this study, FFA has a single feedback mechanism
which inhibits its turnover (6), while in previous studies, FFA was
modeled using an additional feedback mechanism which stimulates
its fractional turnover (7)
Table 1 Summary of experimental protocols—including conscious or anesthetized state, route of administration, duration of experiment,
protocol name, and the number of lean and obese rats within each experiment (the number of saline infused controls is given in parenthesis)
Admin. route Pre-treat. (h) Acute exp. (h) Protocol Number of rats
Lean rats Obese rats
Conscious animals Subcutaneous inf. 0 5 NiAc Naı¨ve 7 (2) 7 (5)
120 5 Cont. NiAc 6 (2) 8 (2)
120 5 Inter. NiAc 6 (2) 8 (3)
Anaesthetized animals Intravenous inf. 0 1 NiAc Off 1 h 4 (3) 5 (3)
0 1 NiAc Stp-Dwn 1 h 5 (2) 5 (2)
Subcutaneous inf. 0 12 NiAc Off 12 h 5 (2) 4 (2)
0 12 NiAc Stp-Dwn 12 h 5 (3) 4 (3)
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labeled with both sub-model subscripts (e.g., potency of
NiAc as an FFA inhibitor will be called IC50NF, whereby
the N is for NiAc and the F is for FFA).
NiAc exposure model
The pharmacokinetic properties of NiAc have been thor-
oughly characterized in previous studies [14, 16–19,
21–23, 26]. Ahlstro¨m et al. [16] introduced a two-compart-
ment disposition model with parallel nonlinear (Michaelis-
Menten) elimination for lean Sprague-Dawley rats, and a
one-compartmental model with a single nonlinear elimina-
tion for obese Zucker rats (a schematic illustration of the PK
models is given in Fig. 2).
Lean rats
In lean rats, the NiAc disposition is given by
Vp  dCpðtÞ
dt
¼ InputðtÞ þ Synt Vmax1  CpðtÞ
Km1 þ CpðtÞ
 Vmax2  CpðtÞ
Km2 þ CpðtÞ  Cld  CpðtÞ
þ Cld  CtðtÞ;
ð1Þ
Vt  dCtðtÞ
dt
¼ Cld  CpðtÞ  Cld  CtðtÞ; ð2Þ
where CpðtÞ is the observed NiAc concentration in the
central plasma compartment and CtðtÞ is the concentration
in the peripheral tissue compartment (derivations of the
initial conditions for these compartments are given in
Appendix 2), and Vp and Vt are, respectively, the volumes
of distribution of the plasma and tissue compartments. The
parameters Vmax1 and Km1 are the maximal elimination rate
and the Michaelis constant of the first pathway, and Vmax2
and Km2 are the maximal elimination rate and the
Michaelis constant of the second pathway (low and high
affinity pathway, respectively). Furthermore, Cld is the
inter-compartmental distribution, Synt the endogenous
NiAc synthesis, and InputðtÞ is a time-dependent function
determined by the route of administration according to
InputðtÞ ¼ Inf. rate Intravenous infusion
ka  AscðtÞ Subcutaneous infusion;

ð3Þ
where Inf. rate is the infusion rate, AscðtÞ is the amount of
drug in the subcutaneous compartment, and ka is the
absorption rate from the subcutaneous compartment to
plasma. The rate of change of AscðtÞ is given by
dAscðtÞ
dt
¼ Pump rate ka  AscðtÞ; ð4Þ
with initial condition Ascð0Þ ¼ 0. Here, Pump rate repre-
sents the infusion rate from a subcutaneous mini-pump.
The mini-pump was surgically implanted seven days
before the final acute experiment. During this period, when
the pump is not infusing, interstitial tissue fluid may diffuse
into the tip of the catheter, diluting the NiAc dosing
solution, whilst the solution is leaking into the tissue.
Consequently, a concentration gradient may form, resulting
in an apparently lower initial infusion rate compared to the
pre-programmed setting (particularly pronounced in lean
NiAc naı¨ve rats, see Fig. 7a). To capture this, the pump
infusion rate is modeled as
Pump rate ¼ Inf. rate  erf t  dﬃﬃﬃ
t0
p
 
; ð5Þ
where Inf. rate is the programmed infusion rate of the
pump, d is a lumped diffusion parameter, and t0 is the
pump inactivation time (in this case 7 days). Here erf is the
error function [27]. The derivation of the Pump rate is
given in Appendix 1. Given NiAc’s low molecular weight
(123.11 g/mol), bioavailability from the subcutaneous
compartment was assumed to be equal to unity.
Obese rats
For obese Zucker rats, the NiAc disposition is given by
Fig. 2 NiAc disposition models for lean Sprague-Dawley (a) and
obese Zucker rats (b). NiAc is either infused directly into the central
compartment (intravenous administration) or absorbed via a subcu-
taneous compartment (subcutaneous administration via an implanted
mini-pump)
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Vp  dCpðtÞ
dt
¼ InputðtÞ þ Synt Vmax1  CpðtÞ
Km1 þ CpðtÞ ; ð6Þ
where CpðtÞ is the NiAc concentration in the central plasma
compartment, Vc the volume of distribution, Vmax1 the
maximal elimination rate, Km1 the Michaelis constant, and
Synt the endogenous synthesis. The term InputðtÞ is the
same as for the lean rats (the relations given in Eqs. 3, 4
and 5).
Between-subject and residual variability
The modeling was performed in an NLME framework to
capture the between-subject variability seen in the expo-
sure-time data. The parameters that varied within the
population were ka, Vmax1, and Synt, though Synt varied
only in lean rats. These were assumed to be log-normally
distributed in order to keep the parameter values positive.
However, the five-day continuous infusion group of obese
rats did not have exposure data. Consequently, these rats
were assumed to behave like the estimated median indi-
vidual. The residual variability was normally distributed
and modeled using a proportional error model.
Estimated parameters
Because of sparse sampling, all parameter values could not
be estimated from the data. By applying an a priori sen-
sitivity analysis [28, 29], we identified the parameters that
had the greatest influence on the output. These were then
estimated from the data and the remaining parameters were
obtained from the literature [23]. The population parame-
ters estimated from the data were ka, d, and Vmax1.
Insulin turnover model
The primary aim of the insulin model was to establish
smooth trajectories that would accurately describe the
insulin-time courses under various provocations of NiAc,
rather than describe all of the mechanistic aspects of insulin
dynamics. To this end, the model structure was kept as
simple as possible. The insulin model could subsequently
be used to provide an input to the FFA model, enabling a
quantitative analysis of the antilipolytic effects of insulin.
Given this premise, a phenomenologically based modeling
approach was applied. Under the assumption that NiAc
perturbs insulin, the characteristics seen in the data were
used to establish an insulin model with NiAc as input. The
characteristic behavior of the data for acute and long-term
NiAc provocations in lean and obese rats is illustrated in
Fig. 3. Attributes seen include indirect action, tolerance
(drug resistance), rebound, and complete adaptation
(insulin levels returning to pre-treatment levels). Data with
similar properties as those seen in the acute experiments
(Fig. 3a, c) were modeled using turnover equations with
moderator feedback control [14, 30]. Furthermore, to
capture the different long-term adaptive behaviors with
(Fig. 3b), and without (Fig. 3d) rebound, a ’NiAc action
compartment’ was included, as well as an integral feedback
control. The insulin dynamics are given by
dIðtÞ
dt
¼ kinI  RIðtÞ  HNIðCpðtÞÞ  M0I
M1IðtÞ
 koutI M2IðtÞ
M0I
 IðtÞ;
ð7Þ
dM1IðtÞ
dt
¼ ktolI  IðtÞ M1IðtÞð Þ; ð8Þ
dM2IðtÞ
dt
¼ ktolI  M1IðtÞ M2IðtÞð Þ; ð9Þ
with initial conditions
Ið0Þ ¼ I0; ð10Þ
and
M1Ið0Þ ¼ M2Ið0Þ ¼ M0I ¼ I0; ð11Þ
where I(t) denotes the observed insulin level, and M1IðtÞ
and M2IðtÞ the first and second moderator compartments,
respectively. The parameters kinI and koutI are the turnover
rate and fractional turnover rate of insulin, respectively,
and ktolI is the fractional turnover rate of the moderators.
The regulator compartment RIðtÞ is given by
dRIðtÞ
dt
¼ kinRI  koutRI  IðtÞ; RIð0Þ ¼ 1; ð12Þ
where kinRI is the turnover rate, koutRI the fractional turn-
over rate, and I(t) the insulin concentration. The regulator
compartment is initially at steady-state with
dRIð0Þ
dt
¼ kinRI  koutRI  I0 ¼ 0 () I0 ¼ kinRI
koutRI
: ð13Þ
By integrating Eq. 12, the dynamics of RIðtÞ can be
expressed as
RIðtÞ ¼ 1þ
Z t
0
kinRI  koutRI  IðsÞ ds: ð14Þ
Hence, by construction, RIðtÞ represents the output of an
insulin-driven integral feedback controller [31] with I0 as
the set-point and koutRI as the integral gain parameter (koutRI
will from here on be referred to as the integral gain
parameter). The integral feedback controller will ensure
that insulin levels return to the baseline I0, despite persis-
tent external effects on insulin turnover and fractional
turnover. The inhibitory NiAc function on insulin is given
by
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HNIðCpðtÞÞ ¼ 1 ENIðNIðtÞÞ 
CnpðtÞ
ICn50NI þ CnpðtÞ
; ð15Þ
where IC50NI is the potency of NiAc on insulin and n the Hill
coefficient of the inhibitory function. The term ENIðNIðtÞÞ
represents the drug efficacy, which is fixed for lean rats and
dependent on the concentration in a hypothetical NiAc
action compartment, NIðtÞ, for obese rats, according to
ENIðNIðtÞÞ ¼
ImaxNI lean
ImaxNI 1 SNI  N
c
I ðtÞ
N
c
50I þ NcI ðtÞ
 
obese;
8<
:
ð16Þ
where ImaxNI is the initial efficacy of NiAc on insulin, N50I
the potency of the NiAc action compartment, SNI the long-
term NiAc efficacy loss, and c the corresponding Hill
coefficient of the efficacy relation. The dynamics of NI are
in turn given by
dNIðtÞ
dt
¼ kNI  ðCpðtÞ  NIðtÞÞ; ð17Þ
with NIð0Þ ¼ Cpð0Þ. Here kNI is the turnover rate of the
NiAc action concentration.
The NiAc action compartment is initially at steady-state
with the plasma NiAc compartment Cp. As infusions begin,
and the plasma compartment concentration increases, NIðtÞ
increases until it reaches the steady-state NiAc concentration
NssðtÞ ¼ Cpss. With increasing levels in the NiAc action
compartment, EðNIðtÞÞ decreases to a minimum of 1 SNI
and, consequently, the efficacy of NiAc as an insulin inhi-
bitor is down-regulated. In other words, the system has
developed tolerance to the drug. The turnover rate kNI
determines the rate at which tolerance develops. A schematic
illustration of the insulin model is given in Fig. 4.
Between-subject, inter-study, and residual variability
Individual variations seen in the insulin data were incor-
porated in the model by allowing the parameters I0, ktolI,
and IC50NI to vary in the population. As in the PK model,
these parameters were assumed to be log-normally dis-
tributed. The choice of these parameters was guided by an
a priori sensitivity analysis. Moreover, the parameters I0
and ktolI varied over study groups according to fixed-study
effects on both the mean and individual parameter distri-
butions [25]. In other words, for S, the number of groups,
the parameter I0 for an individual j was modeled as
I0j ¼ ðI01  Study1 þ . . .þ I0S  StudySÞ ð18Þ
expðg1  Study1 þ . . .þ gS  StudySÞ; ð19Þ
where Studyk ¼ 1 if individual j is in group k and 0
otherwise. The residual variability was modeled using an
additive model (with normally distributed errors).
(a) (b)
(c) (d)
Fig. 3 Exploration of insulin-time course data for acute NiAc dosing
(a) and (c), and chronic NiAc dosing (continuous infusion) (b) and
(d) for lean and obese rats, respectively. The data is presented as the
mean response ± the standard error of the mean. The blue lines
represent the NiAc treated animals, the red lines vehicle control
group, and the thick black line represent the NiAc infusion period
(Color figure online)
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Mechanistic FFA model
The model suggested in this study (schematically illus-
trated in Fig. 5) is founded on preceding approaches
[14, 19, 20, 23]; however, insulin has been included as the
main endogenous regulator of FFA as insulin provides a
homeostatic force on the system—thereby keeping FFA
levels in the vicinity of its baseline concentration. Fur-
thermore, the NiAc efficacy is dynamic in that it is
decreasing during long-term infusions, which allows for
complete systemic adaptation - a feature apparent in the
data [32, 33]. The characteristic behavior of the data, for
acute and chronic NiAc provocations in lean and obese
rats, is illustrated in Fig. 6. Attributes observed include
indirect response, tolerance (drug resistance), rebound, and
complete adaptation (FFA concentrations returning to pre-
treatment levels). The behavior observed in the acute
experiment (Fig. 6a, c) has been described by turnover
equations with moderator feedback (as described for the
insulin system). The long-term behavior, and in particular
the adaptations with, and without, rebound, is captured by
dynamic NiAc efficacy and an insulin-controlled regulator.
The FFA model is given by
dFðtÞ
dt
¼ kinF  RðtÞ  HNFðCpðtÞÞ  M0F
MFðtÞ
 koutF  FðtÞ;
ð20Þ
with initial condition
Fð0Þ ¼ F0: ð21Þ
Here, F(t) denotes the observed FFA level, kinF the turnover
rate, and koutF the fractional turnover rate. The moderator
compartment MF is given by
dMFðtÞ
dt
¼ ktolF  FðtÞ MFðtÞð Þ; ð22Þ
with initial condition
MFð0Þ ¼ M0F ¼ F0; ð23Þ
where the parameter ktolF represents the turnover rate of the
moderator compartment. The moderator compartment
provides a feedback mechanism for the turnover of FFA,
that strives to dampen deviations from the baseline
response. The regulator compartment RFðtÞ, that links
insulin dynamics to FFA release, is similar to that of the
insulin model (Eq. 12) and is given by
dRðtÞ
dt
¼ kinRF  koutRF  IðtÞ; Rð0Þ ¼ 1; ð24Þ
where kinRF is the turnover rate, koutRF the fractional turn-
over rate, and I(t) the insulin concentration. As for the
insulin regulator, RFðtÞ represents the output of an insulin-
driven integral controller with I0 as the set-point and koutRF
as the integral gain parameter. The contribution of this
integral controller during acute and chronic NiAc treat-
ments in lean and obese rats is illustrated in Fig. 9b. The
inhibitory NiAc function on FFA (similar to that for the
insulin model, Eq. 15), is given by
HNFðCpðtÞÞ ¼ 1 ENFðNFðtÞÞ 
Cmp ðtÞ
ICm50NF þ Cmp ðtÞ
; ð25Þ
Fig. 5 Mechanisms of FFA dynamics. The parameters kinF and koutF
represent the turnover rate and fractional turnover, respectively. The
turnover of FFA is inhibited by the NiAc action function HNFðCpÞ.
Tolerance and rebound are captured by the moderator compartment
MF, which acts on the turnover rate of FFA. The regulator
compartment R acts on the turnover rate of FFA and the fractional
turnover rate of R is affected by insulin
Fig. 4 Mechanisms of insulin dynamics. The parameters kinI and koutI
represent the turnover rate and fractional turnover rate, respectively.
The turnover of insulin is inhibited by the NiAc action function
HNIðCpÞ. Tolerance and rebound is captured by the moderator
compartments M1I and M2I, which act on the turnover rate and
fractional turnover rate of insulin, respectively. The regulator RI,
representing an integral feedback controller, acts on the turnover rate
of insulin, in that it strives to maintain insulin baseline, I0, despite
persistent external effects on the turnover
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where IC50NF is the potency of NiAc as an inhibitor of FFA
release and m is the Hill coefficient. The drug efficacy is
dynamic and changes (down-regulates) during long-term
infusions of NiAc. The efficacy is given by
ENFðNFðtÞÞ ¼ ImaxNF  1
SNF  N/F ðtÞ
N
/
50F þ N/F ðtÞ
 !
; ð26Þ
where ImaxNF is the initial efficacy of NiAc on FFA, N50F
the potency of the NiAc action compartment, SNF the long-
term NiAc efficacy loss, / the Hill coefficient, and NFðtÞ
the concentration in the NiAc action compartment. The
dynamics of the NiAc action compartment are in turn
described by
dNFðtÞ
dt
¼ kNF  ðCpðtÞ  NFðtÞÞ; ð27Þ
with initial condition NFð0Þ ¼ Cpð0Þ. Here, the parameter
kNF is the turnover rate of the NiAc action state.
Between-subject, inter-study, and residual variability
Random effects were again selected using an a priori
sensitivity analysis. The parameters that varied in the
population were F0, ktolF, and IC50NF (according to a log-
normal distribution). Moreover, inter-study variability was
incorporated in the model according to a fixed-study effect
(as described for the insulin model). The parameters that
varied between experimental groups were F0 and ktolF. The
residual variability was modeled using an additive model
(with normally distributed errors).
Numerical analysis
The NLME modelling and simulations and the identifia-
bility analysis were performed using Wolfram Mathemat-
ica (Wolfram Research, Inc., Mathematica, Version 10.3,
Champaign, IL (2014).
Identifiability analysis
All population model structures analyzed in this study were
proven to be structurally locally identifiable in a fixed
effects setting (identifiability of the population model
(fixed effects) implies identifiability of the statistical model
(random effects) [34]). The identifiability analysis was
performed using the Exact Arithmetic Rank (EAR)
approach [35–37]—implemented in the Identifiabil-
ityAnalysis Wolfram Mathematica package, devel-
oped by the Fraunhofer-Chalmers Centre. The EAR
algorithm requires that all states and system parameters are
rational functions of their arguments. This requirement is
not fulfilled in the insulin and FFA systems (for example,
the state space variable Cp is raised to the power of n in
Eq. 15). An illustrative example of how this requirement
can be achieved is provided in the Appendix 3.
(a) (b)
(c) (d)
Fig. 6 Exploration of FFA-time course data for acute NiAc dosing
(a) and (c), and chronic NiAc dosing (continuous infusion) (b) and
(d) for lean and obese rats, respectively. The data is presented as the
mean response ± the standard error of the mean. The blue lines
represent the NiAc treated animals, the red lines vehicle control
group, and the thick black line represent the NiAc infusion period
(Color figure online)
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Selection of random effect parameters
An a priori sensitivity analysis was used to guide selection
of the random parameters [28, 29]. The system output
sensitivity, with respect to the parameters, was analyzed
and the parameters were ranked accordingly. The param-
eters with the highest sensitivity, given by the absolute
value of the partial derivative of the system output with
respect to a specific parameter evaluated at a given point in
the parameter space, were considered random in the model.
Parameter estimation
Parameter estimates for the NLME models were computed
by maximizing the first-order conditional estimation
(FOCE) approximation of the population likelihood. This
was done using a method developed and implemented in
Mathematica 10 (Wolfram Research) at the Fraunhofer-
Chalmers Research Centre for Industrial Mathematics
(Gothenburg, Sweden) [38], which combines exact gradi-
ents of the FOCE likelihood based on the so-called sensi-
tivity equations with the Boyden-Fletcher-Goldfarb-
Shanno optimization algorithm [39]. Parameter standard
errors were derived using the Hessian of the approximate
population likelihood with respect to the parameters,
evaluated at the point estimate. The Hessian was computed
using finite differences of the exact gradients.
From the steady-state relations in the insulin and FFA
models, dependencies were derived which enabled the
parameters kinI, kinF, kinRI, and kinRF to be expressed in
terms of other model parameters (derivation given in
appendix 2). Consequently, these parameters were redun-
dant and could be replaced in the parameter estimation.
Furthermore, some parameters were initially estimated to
be very close to their physiological limit (e.g. ImaxNI ¼
0:9999  1 for obese rats) and were consequently fixed for
numerical stability. Finally, to simplify the parameter
estimation, some parameters were fixed (e.g., SNI ¼ 1 for
obese rats). This is motivated by the complete systemic
adaptation apparent in the long-term insulin-time data
(obese rats), implying that SNI must be 1 (The fixed
parameters are given in Table 2)). The long-term NiAc
efficacy loss for lean rats was initially estimated to be  0,
whereby this part was omitted in the final model.
Results
The parameter estimation for the three sub-models (NiAc,
insulin, and FFA) was performed sequentially, as described
in the Model development section. The estimates and
between-subject variabilities (expressed in CV%), both
with corresponding relative standard errors (RSE%), for
normal Sprague-Dawley rats and obese Zucker rats are
given in Table 2. Weighted summaries [25] are presented
for the parameters that varied between studies. The
resulting models were qualitatively evaluated using visual
predictive check (VPC) plots [40]; illustrating the data, the
model predicted median individual, and 90% Monte Carlo
prediction intervals generated from the models [40, 41].
The VPC’s are shown in Fig. 7 for lean Sprague-Dawley
rats and in Fig. 8 for obese Zucker rats. The VPC’s are
generated from the PK, insulin, and FFA models for all
provocations of NiAc.
Pharmacokinetic model
The pharmacokinetic system reached a steady-state con-
centration of about 1lM for all protocols both in lean and
obese rats (first column in Fig. 7 and first column in Fig. 8).
The steady-state was attained faster with intravenous than
with subcutaneous administration. When infusions were
terminated, the drug was cleared from the system within
minutes and the NiAc concentration approached the
endogenous level.
The absorption from the subcutaneous compartment had
a half-lives of 0.16 and 0.13 h for lean and obese rats,
respectively. At steady-state, the elimination of NiAc from
the plasma compartment in lean rats was approximately
three times faster for the high affinity pathway than the low
affinity one. Moreover, the drug elimination rate from the
plasma at steady-state was  20 and  25lmolkg1h1 for
lean and obese rats, respectively. The lumped diffusion
coefficient was estimated to be 77 and 62 h1=2 for lean
and obese rats, respectively, implying that the NiAc dosing
solution was diluted during the first  1.5 h.
Insulin model
The insulin concentration was suppressed below its base-
line value at all provocations of NiAc. The suppression was
more pronounced at an early stage of the infusions; at later
stages, the insulin concentrations drifted back towards their
baselines (cf. Figs. 7b–h or 8b–h). After the infusions were
terminated, the insulin concentration rebounded before
reaching its baseline value. Rebound was highest in the rats
receiving the 12 h Off protocols (Figs. 7k, 8k) and was less
pronounced in those receiving step-down protocols
(Figs. 7n, t, 8n, t). In obese rats, the insulin concentrations
returned to their baselines after long-term infusions of
NiAc and did not rebound after the extended infusions
were terminated (Fig. 8h).
The median baseline concentrations across groups were
0.233 and 3.51 nM for lean and obese rats, respectively.
The estimates of the individual groups ranged between
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Table 2 Estimates of parameter median values and between-subject
variabilities with corresponding relative standard errors (RSE%) for
normal Sprague-Dawley rats and obese Zucker rats. Estimates
highlighted in blue were taken from the literature (Tapani et al.
[23]) while the remaining parameters were estimated in this study
Normal Sprague-Dawley rats Obese Zucker rats
Parameter Definition Estimate (RSE%) BSVa (RSE%) Estimate (RSE%) BSVa (RSE%)
Pharmacokinetic model parameters
ka (h
1) First order absorption rate 4.27 (13) 80.1 (51) 5.54 (16) 80.2 (47)
d (h1=2) Lumped diffusion coeff. catheter 77.4 (15) – 62.4 (17) –
Vmax1 (l mol kg1h1) Max. elimination - pathway 1 2.64 (12) 93.5 (51) 164 (5.1) 22.4 (13)
Km1 (lM) Michaelis constant - pathway 1 0.235 (29.2) – 18.9 (21.5) –
Vmax2 (lmol kg1h1) Max. elimination - pathway 2 425 (39.6) – – –
Km2 (lM) Michaelis constant - pathway 2 74.5 (43.4) – – –
Vp (L kg
1) Volume of distribution - plasma 0.393 (5.29) – 0.323 (12.4) –
Vt (L kg
1) Volume of distribution - tissue 0.172 (35.2) – – –
Cld (L kg
1h1) Inter-compartmental distribution 0.0511 (27.8) – – –
Synt (lmol kg1h1) Endogenous NiAc synthesis 0.213 (23.3) 66.7 (57) 0.168 (10.1) 95 (110)
rpropN Residual proportional error 0.313 (5.1) – 0.483 (5.3) –
Insulin model parameters
I0 (nM) Baseline insulin conc. 0.188 (9.7) 49.3 (5.5) 3.26 (12) 10.3 (21)
koutI (h
1) Fractional turnover rate insulin 6.58 (14) – 10.8 (17) –
ImaxNI Efficacy - NiAc on insulin 0.793 (11) – 1b –
IC50NI (lM) Potency - NiAc on insulin 0.338 (15) 111 (67) 0.175 (27) 190 (160)
n Hill coefficient - NiAc on insulin 3.54 (6.6) – 0.840 (6.0) –
ktolI (h
1) Turnover rate moderator 0.646 (28) 93.9 (20) 0.125 (48) 310 (9.4)
koutRI (nM
1h1) Integral gain parameter 3.94 (17) – 0.0612 (27) –
kNI (h
1) Turnover rate NiAc action comp. – – 0.0242 (35) –
N50I (lM) Potency NiAc action compartment – – 0.897 (4.9) –
c Hill coefficient – – 18.9 (44) –
SNI Long-term NiAc effect loss – – 1b –
raddIðnMÞ Residual additive error 0.0699 (3.3) – 0.748 (3.0) –
Free fatty acid model parameters
F0 (mM) Baseline FFA conc. 0.707 (5.0) 17.8 (26) 1.14 (3.1) 0.874 (25)
koutF (h
1) Fractional turnover rate FFA 428 (140) – 173 (120) –
ImaxNF Efficacy - NiAc on FFA 1b – 1b –
IC50NF (lM) Potency - NiAc on FFA 0.436 (12) 41.8 (28) 0.456 (14) 41.8 (26)
m Hill coefficient - NiAc on FFA 1.24 (11) – 0.731 (9.0) –
ktolF (h
1) Turnover rate moderator 1.21 (67) 58.4 (9.6) 0.708 (24) 34.2 (15)
koutRF (nM
1h1) Integral gain parameter 0.965 (29) – 0.0165 (38) –
kNF (h
1) Turnover rate NiAc action comp. 0.00654 (65) – 0.0377 (14) –
N50F (lM) Potency NiAc action compartment 3.05 (160) – 0.854 (4.5) –
/ Hill coefficient 1b – 8.83 (33) –
SNF Long-term NiAc effect loss 0.807 (190) – 1b –
raddFðmMÞ Residual additive error 0.130 (3.5) – 0.135 (3.0) –
a Between-subject variability expressed in CV%, calculated as 100
ﬃﬃﬃﬃﬃﬃ
x2
p
.
b Fixed in the estimations.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m) (n) (o)
(p) (q) (r)
(s) (t) (u)
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0.151 and 0.264 nM (inter-study variability of 33%1) for
lean rats and 2.69–4.82 nM (inter-study variability of
33%1) for obese rats. The inter-study variability was not
correlated to the anesthetic condition of the rats. The
median turnover half-lives of insulin, for the moderator, the
integral controller, and the NiAc action level for lean and
obese rats are given in Table 3. For lean rats, the efficacy of
NiAc on insulin inhibition, ImaxNI, was estimated to be
0.793; consequently, NiAc cannot completely inhibit
insulin release. The established NiAc exposure was about
1lM which is approximately three times the NiAc potency
related to inhibition of insulin (IC50NI ¼0.338 lM). This
implies that the inhibitory function was saturated at steady-
state. The estimated Hill coefficient n indicates a steep
NiAc concentration-insulin response relationship at steady-
state. Furthermore, for obese rats, the efficacy was fixed to
1 (described in the parameter estimation section) and the
corresponding potency was high since the IC50NI was low
in comparison to the NiAc steady-state exposure. However,
since the estimated Hill coefficient was 0:84\1, indicating
a gentle NiAc-concentration insulin-response relationship
at steady state, the NiAc concentrations never reached
levels high enough to saturate the inhibitory function. The
estimated N50I of the NiAc action compartment was lower
than the steady-state NiAc concentration (0.897\1) and the
Hill coefficient of the dynamic efficacy was estimated to be
18.9 (suggesting an all or non-response). This implies that
the efficacy was completely down-regulated at the end of
the long-term experiments in obese rats, implying no NiAc
inhibition on insulin release.
FFA model
The FFA concentration was suppressed below its baseline
value for all provocations of NiAc. Suppression was more
pronounced initially during NiAc infusions. FFA concen-
trations then drifted back towards their baseline values (cf.
Figs. 7c–f or 8c–i). After the infusions were terminated, the
FFA concentrations rebounded before reaching their
baseline values. The step-down protocols resulted in less
rebound. The FFA concentrations returned to their baseli-
nes during extended exposure of NiAc in lean and obese
rats (Figs. 7f, 8i, respectively). However, as the long-term
exposure was terminated, rebound occured in lean, but not
in obese rats (Figs. 7f, 8i). The median baseline concen-
trations across groups were 0.707 and 1.14 mM with cor-
responding ranges of 0.652–0.801 mM (inter-study
variability of 11%2) in lean and 0.789–1.22 mM (inter-
study variability of 20%2) obese rats, respectively. The
inter-study variability was not correlated to the anesthetic
condition of the rats. The median turnover half-lives of the
FFA, the moderator, the integral controller, and the NiAc
action level are given in Table 3.
Model simulations of the acute and chronic action of NiAc
(HNFðCpðtÞÞ), the insulin-driven integral controller (RFðtÞ—
also referred to as the insulin-controlled regulator), and the
moderator feedback (M0F=MFðtÞ) on the FFA turnover are
illustrated in Fig. 9 with the corresponding acute and chronic
FFA responses. The simulated NiAc concentrations were set
to be around 1lM (corresponding to the experimental
exposures). The turnover rate of FFA was initially inhibited
about 80% (lean) and 70% (obese) by the NiAc infusion
(Fig. 9a). Upon the extended exposure to NiAc (120 h) the
inhibitory action on the turnover rate was decreased by
approximately 13% due to intrinsic tolerance mechanisms
(Eq. 26). In obese rats, the NiAc action vanished completely
(Fig. 9a). The insulin-driven controller (Eq. 14) provides a
stimulatory action on the FFA turnover rate as insulin con-
centrations fall below the baseline (Fig.9b). The positive
(stimulatory) action increases from 100% (at baseline) to
about 200% after extended (120 h) exposure to NiAc in lean
rats. The insulin action is totally abolished at equilibrium
(120 h) in obese rats (Fig. 9b). The positive impact of the
moderator is seen acutely both in lean and obese rats,
whereas the moderator action has receded in obese rats at
equilibrium (Fig. 9c). In lean rats, the combined inhibitory
(NiAc) and stimulatory (insulin, moderator) action on the
FFA turnover rate causes a rebound in FFA response when
the NiAc infusion is stopped (Fig. 9d). This is not seen in
obese rats since all of the NiAc, insulin, and moderator
actions are back to baseline at equilibrium (120 h).
The potency of the NiAc action compartment was low
for lean rats, since N50F [ [NðtÞ at equilibrium (120 h),
and high for obese rats, since N50F\NðtÞ at equilibrium
(120 h). Consequently, the loss of efficacy was low in lean
rats and high in obese ones. Furthermore, the estimate of
Hill coefficient / ¼ 8:37 for obese rats suggests an all-or-
none efficacy loss in obese rats.
Model predictions
The resulting model was used to predict 24 h FFA lowering
(AUC24) for a range of protocols at steady-state (i.e., after
multiple dosing). Here, the lowering over a period T is
given by
bFig. 7 Visual predictive checks for lean Sprague-Dawley rats. The
first column shows the PK fit, the second column the insulin, and the
third column the FFA. The rows represent the different protocols of
NiAc (as described in the Experimental protocols section). The dots
represent the data, with colors indicating separate individuals, the
black line the estimated median individual, and the grey area the 90%
population prediction interval
1 Expressed in CV% 2 Expressed in CV%
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AUCT ¼ F0  T 
Z T
0
FðsÞ ds: ð28Þ
The protocol design consisted of a 0.25–12 h NiAc expo-
sure period followed by a 0–12 h washout period. The
NiAc infusions were designed to generate concentrations
around the therapeutically relevant level ( 1lM) that was
used in the experiments [16]. The predicted AUC24 and
proportional reduction, in comparison to baseline levels, on
a median obese rat are given in Fig. 10. The model pre-
dicted an optimal dosing strategy of  2 h longer washout
period than the exposure period and the maximal AUC
reduction is 5.60 mM h. These results were consistent
when AUC24 was predicted for outliers with high/low
potencies (IC50NF), baseline responses (F0), and/or mod-
erator turnover rates (ktolF).
Furthermore, the NiAc-concentration FFA-response
relationship at steady-state, for obese rats, is illustrated in
Fig. 11, with the corresponding NiAc-, insulin-, and
moderator actions. The largest reductions in FFA exposure
occurs within a ‘window of opportunity’, with NiAc con-
centrations between the IC50NF and the N50F. The predicted
AUC24 at steady-state, for the optimal NiAc exposure of
0.500lM, was 7.40 mM h.
Discussion
In this study, we applied a population modeling approach
to a unique pre-clinical data set containing FFA-, insulin-,
and NiAc-time courses obtained from acute and chronic
provocations of NiAc in lean and obese rats. The aim was
to identify a general model, from a macro perspective, to
be used to predict optimal NiAc exposure profiles and to
generate durable chronic dosing regimens.
Recent experimental data from long-term NiAc proto-
cols have illustrated adaptation, with FFA concentration
returning to its baseline value [15]. Those findings chal-
lenge previous models [18, 23] for long-term dosing
predictions.
The PK/PD model applied in this study was derived
based on previous models [18, 20, 23], but we added,
crucial mechanistic components in order to describe two
different kinds of complete adaptation, one seen in lean
rats and one in obese. In particular, insulin was included
as an endogenous regulator of the turnover of FFA [9]. To
this end, a separate insulin model was developed to
describe the insulin dynamics for all provocations of
NiAc.
Model characteristics
A key observation of the FFA-time course data in our
study is that lean and obese rats both acquire complete
adaptation, with FFA levels returning towards baseline at
equilibrium (Fig. 6). The post-infusion FFA rebound in
lean rats implies a NiAc-sensitive system. However, the
rebound was less pronounced than that for the 1–12 h
experiments. Consequently, the inhibiting effect of NiAc
has been down-regulated during the long-term infusions.
For obese rats, the rebound completely vanished, which
implies a NiAc-insensitive system. This suggests two
separate mechanisms that result in complete adaptation.
To describe adaptation with drug effect (seen in lean rats),
an insulin-driven integral feedback control was incorpo-
rated into the model [39]. Control system techniques have
previously been applied in glucose-insulin models in form
of PID (proportional-integral-derivative) controllers [42].
The set-point of the insulin-driven integral controller is
the insulin baseline and, hence, its action reflects the
deviations from baseline insulin concentrations. For the
FFA model, the controller represents the antilipolytic
effect of insulin [24] via a regulator; as the insulin level
increases, the antilipolysis will be more pronounced since
the elimination rate of RF will increase and, consequently,
RF’s stimulation of FFA release will be lowered (and vice
versa). The traditional Imax-equation was modified with a
dynamic efficacy function in order to capture the phe-
nomena of NiAc resistance. The dynamic efficacy may
represent the down-regulation of the PDE3B gene
expression [7].
The impact of the dynamic efficacy and the integral
controller (Fig. 9) show that both adaptive actions push
FFA concentrations back towards baseline (at equilibrium)
bFig. 8 Visual predictive checks for obese Zucker rats. The first
column shows the PK fit, the second column the insulin, and the third
column the FFA. The rows represent the different protocols of NiAc
(as described in the Experimental protocols section). The dots
represent the data, with colors indicating separate individuals, the
black line the estimated median individual, and the grey area the 90%
population prediction interval. No exposure data were available from
the Cont. protocol (g).
Table 3 Turnover half-lives (expressed in hours) in the insulin and
FFA model for lean and obese rats of the biomarkers (insulin or
FFA—corresponding rate constant kout), the moderator (rate constant
ktol), the integral controller (rate constants koutR), and the NiAc action
(rate constant kN)
Half-lives (h)
Lean rats Obese rats
Turnover Insulin FFA Insulin FFA
Biomarker 0.105 0.00162 0.0643 0.00401
Moderator 1.07 0.570 5.53 0.979
Controller 0.176 0.719 11.3 42.0
NiAc action – 106 28.7 18.4
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despite ongoing NiAc exposure. The insulin-driven con-
troller has less effect in obese as compared to lean rats in
spite of 10-fold higher insulin concentrations in the former
group. This reflects the insulin resistance of the obese rats
[7].
Model evaluation
The VPC’s (Figs. 7, 8) demonstrate the flexibility of the
insulin and FFA models in that response-time courses were
captured in both acute and chronic settings. The fractional
(a) (b)
(c) (d)
Fig. 9 Model simulations of acute and chronic action of NiAc
exposure HNF (a), insulin-driven integral control (b), and moderator
feedback (c) on the FFA turnover. Acute and chronic FFA response
(d). Red lines show lean rats and black lines obese rats. The dashed
lines show the baseline FFA response (Color figure online)
(a) (b)
Fig. 10 Model predicted reduction in FFA exposure in a median
obese rat at steady-state (i.e., after multiple dosing). (a) illustrates the
predicted average reduction in 24 h FFA area under the curve and (b)
illustrates the proportional reduction, in comparison to the baseline
level. The predictions are made for a range of infusion protocols with
0.25–12 h of NiAc exposure followed by 0–12 h washout period. The
x-axis represents the infusion time and the y-axis represents the
washout time. The model predicts an optimal infusion regimen of
 2-h longer washout period than the infusion. The maximal AUC
reduction is 5.60 mM h
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turnover rate is operating on a significantly shorter time-
scale than the feedback and adaptive mechanisms. This
resulted in low precision of koutF (RSE% of 140 and 120,
respectively, in lean and obese rats). To achieve higher
precision a denser sampling of the FFA time-course is
needed during the initial infusion phases. On the other
hand, the drug resistance in lean rats was a slower process
(half-life of the NiAc action of more than 100 h). This
resulted in low precision of the parameters linked to effi-
cacy loss (RSE% of 160 for kNF and 190 for SNF).
Some estimated median responses of the insulin and
FFA models were under- or over-predicted (cf. Fig. 7l or
Fig. 7k). This is most likely due to the low number of
individuals per trial (5–10), implying that every 4-9th
population median will be estimated below or above the
trends seen in the individual data [43]. Furthermore, some
predicted 90% population spans also under- or over-pre-
dicted the response for the insulin and FFA model (cf.
Fig. 7l or Fig. 7k). This is most likely due to correlations of
the between-subject parameter variabilities, which were not
captured because diagonal covariance matrices were used
in the FFA model [44]. When sampling from the resulting
distributions to generate the VPC’s, non-feasible parameter
combinations may occur which render a skewed population
[44]. Diagonal covariance matrices were chosen in order to
simplify the parameter estimation.
The turnover processes in the insulin and FFA models
operate over completely different time scales (Table 3).
The general trend in both models is that the moderator and
integral controller processes are slower in obese rats. For
example, the insulin-driven integral controller has a half-
life that is 50 times longer in obese as compared to lean
rats. These control processes are tightly controlled in lean
animals, and are probably elongated by the tremendous
hyperinsulinemia (nearly 10-fold greater pathological
concentrations), and corresponding insulin resistance, in
obese rats. In the FFA model, turnover of FFA is more than
100 times faster than moderator feedback and integral
control. Furthermore, turnover of the NiAc action com-
partment had a half-life of more than 100 h for lean rats,
thus spanning the entire duration of the experiment. The
corresponding half-life in obese rats was 18 h. Hence,
obese rats reach complete adaptation much faster than lean
rats.
Due to the nature of the FFA dynamics, with tolerance
development and rebound post-infusions, constructing an
optimal dosing protocol is challenging. By selecting an
inappropriate dosing regimen, the NiAc provocation can
yield an increased FFA exposure in comparison to controls
(Fig. 10—the negative AUC area). Given a NiAc exposure
of  1lM (the exposure that was used in the experiments),
there is an optimal strategy whereby washout periods are
2 h longer than infusion periods; this is illustrated by
Fig. 10. These strategies were consistent in that they were
tested on the median individual and on 90% quantiles (i.e.,
individuals that had the 5 and 95% quantiles of the
parameters that varied in the population: IC50NF, F0, and
ktolF). However, rather surprisingly, higher reductions in
AUC were attained at constant NiAc exposure (without
washout periods) at lower concentrations, where the max-
imal reduction was 7.40 mM h (in comparison to the
maximal reduction of 5.60 mM attained from the exposure/
washout protocols).
Conclusions
Our study presents a novel NiAc-insulin-FFA model that
could accurately describe the concentration-response rela-
tions seen during acute and chronic NiAc treatment in lean
Sprague-Dawley and obese Zucker rats. In particular the
model could describe two different types of adaptive
changes. This was done by applying an insulin-driven
integral controller and a dynamic efficacy in the traditional
Fig. 11 Predicted steady-state
concentration-response (left-
hand y-axis) and concentration-
action (right-hand y-axis)
relationships for obese rats. The
black line represents the FFA
response, the blue line the
inhibitory action of NiAc on
FFA turnover, the red line the
insulin action on FFA turnover,
and the purple line the
moderator action on the FFA
turnover. The IC50F and the N50F
concentrations are given by the
black vertical lines (Color
figure online)
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Imax model. The dynamics of these methods make them
suitable for a range of tolerance scenarios. Finally, the
model was used to simulate infusion-washout regimens,
with a NiAc exposure of 1lM, in order to estimate the 24 h
lowering of FFA. Given the targeted exposure, the
importance of incorporating washout periods in-between
infusions was illustrated. However, the predicted concen-
tration-response relationship suggests that higher reduc-
tions in AUC could be obtained by using lower NiAc
concentrations. These findings should be experimentally
verified in future studies.
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Appendix 1: Diffusion model
The first-order absorption model did not sufficiently
describe the full kinetics of the NiAc after subcutaneous
administration due to an initial NiAc concentration gradi-
ent in the implanted mini-pump catheter. There is a
recovery period of 7 days before the experiment begins and
the pumps are set into action. During this period, tissue
fluid diffuses into the catheter, whilst the drug is leaking
into the tissue, which gives rise to a concentration gradient
in the catheter. This results in a lower initial infusion rate
of NiAc.
The concentration gradient is described by Eq. 5 which
is derived by viewing the catheter as a one-dimensional
diffusion problem. The one-dimensional fluid equation has
the solution
cðx; tÞ ¼ c0  erfc x
2
ﬃﬃﬃﬃ
d^t
p
 !
; ð29Þ
where c0 is the concentration at the boundary (where the
fluid diffuses from), x is the diffusion direction, t is the
time, d the diffusion parameter, and erfc the complemen-
tary error function [27]. Given that the intestinal fluids take
the form given in Eq. 29, the NiAc concentration in the
catheter will, due to symmetry, be scaled by the factor
erf
x
2
ﬃﬃﬃﬃ
d^t
p
 !
; ð30Þ
where erf is the error function [27]. Now, assume that the
diffusion is negligible after the infusions start and, conse-
quently, only the time between implantation and initiation
of the pump, given by t0, affects the concentration gradient.
Then the infusion rate will be scaled by the factor in Eq. 29
with t ¼ t0. The direction can be expressed as x ¼ v  t
where v is the infusion velocity and t is the time after the
infusion has started. The velocity is fixed in the experiment
and can be lumped with the factor 1
2
ﬃﬃ^
d
p , as
d ¼ v
2
ﬃﬃﬃ^
d
p ; ð31Þ
and the rate is scaled by
erf
t  dﬃﬃﬃ
t0
p
 
ð32Þ
where the parameter d is estimated from the data.
Appendix 2: Steady-state relations
The system given in Eqs. 1 and 2 is at steady-state at t ¼ 0,
and after a couple of minutes, with
dCpðtÞ
dt
¼ 0. Given this,
we can solve for the steady-state concentration Cpss(¼ Ctss)
as
Vc  dCpss
dt
¼ inputþ Synt|ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
¼
a Vmax1  Cpss
Km1 þ Cpss 
Vmax1  Cpss
Km1 þ Cpss
þ Cld  Ctss  Cld  Cpss|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
¼0
¼ 0;
ð33Þ
this gives rise to a quadratic equation with the positive real
root
Cpss ¼ bþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2  4ac
p
2a
: ð34Þ
Here
a ¼ a Vmax1  Vmax2 ð35Þ
b ¼ a  ðKm1 þ Km2Þ  Vmax1  Km2  Vmax2  Km1; ð36Þ
and
c ¼ a  Km1  Km2: ð37Þ
Consequently, the initial steady-state concentration is given
by Eqn, 34 with Const. ¼ Synt and the steady-state
attained after a couple of minutes of infusion is given by
Eqn. 34 with Const. ¼ inputþ Synt.
Assuming that the system in Eq. 7 is at an initial steady-
state with dI
dt
¼ 0 and that the initial plasma concentration of
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NiAc is close to zero, i.e. Cpð0Þ  0, the inhibitory NiAc
function on insulin is HNIðCpð0ÞÞ  1 and we obtain
dI
dt
¼ kinI  koutI  I0 ¼ 0 () ð38Þ
kinI ¼ koutI  I0: ð39Þ
Thus, we can eliminate kinI from the estimation procedure
and obtain an estimate for this parameter from Eq. 39.
Assuming that the system in Eq. 20 is at an initial
steady-state with dF
dt
¼ 0 and that the initial plasma con-
centration of NiAc is close to zero, i.e. Cpð0Þ  0, then the
inhibitory NiAc function on insulin is HNFðCpð0ÞÞ  1 and
we obtain
dF
dt

t¼0
¼ kinF 1 ImaxIF  I0
IC50IF þ I0|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ}
0
0
BB@
1
CCA koutF  F0 ¼ 0 () ð40Þ
kinF ¼ koutF  F0: ð41Þ
Thus, we can eliminate kinF from the estimation procedure
and obtain an estimate for this parameter from Eq. 41.[45]
Appendix 3: Identifiability
The insulin system, given by Eqs. 7 to 17, with the NiAc
concentration Cp as input and the insulin level I as output,
does not fulfill the requirement that all states and system
parameters must be rational functions of their arguments
(for example, the state space variable CpðtÞ is raised to the
power of n in Eq. 15). This issue is overcome by intro-
ducing the auxiliary state variable BðtÞ ¼ CnpðtÞ[45] with
dBðtÞ
dt
¼ n  Cn1p ðtÞ 
dCpðtÞ
dt
¼ n  BðtÞ
CpðtÞ 
dCpðtÞ
dt
; ð42Þ
and the parameter B0 as the initial condition
Bð0Þ ¼ B0 ð¼ Cnpð0ÞÞ: ð43Þ
Furthermore, we introduce IB50 as IB50 ¼ ICn50NI. Given
these transformations, the drug mechanism function in
Eq. 15 becomes
HNIðBðtÞÞ ¼ 1 ENIðNðtÞÞ BðtÞ
IB50 þ BðtÞ ; ð44Þ
and the augmented insulin system, with Eq. 42 to 44 with
parameters B0 and IB50 included, will fulfil the require-
ments of the EAR algorithm (this augmented system is
equivalent to the original one). Now, explicit relations such
as B0 ¼ Cnpð0ÞÞ can not be included in the algorithm. This
leaves B0 structurally locally unidentifiable and, conse-
quently, IB50 structurally locally unidentifiable. However,
all other parameters are structurally locally identifiable and
the degree of freedom of the system, given by the algo-
rithm, is 1. Given that we can identify n and that we know
the initial input Cpð0Þ, we can identify B0 from
B0 ¼ Cnpð0ÞÞ. Hence, we can also identify IB50 (since the
degree of freedom was 1) and the system is structurally
locally identifiable.
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